<html><head><title>Optimal Two-Stage Phase II Design with User-specified Combined Sample Size</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<link rel="stylesheet" type="text/css" href="Rchm.css">
</head>
<body>

<table width="100%"><tr><td>np.OptimDes(OptimPhase2)</td><td align="right">R Documentation</td></tr></table><object type="application/x-oleobject" classid="clsid:1e2a7bd0-dab9-11d0-b93a-00c04fc99f9e">
<param name="keyword" value="R:   np.OptimDes">
<param name="keyword" value=" Optimal Two-Stage Phase II Design with User-specified Combined Sample Size">
</object>


<h2>Optimal Two-Stage Phase II Design with User-specified Combined Sample Size</h2>


<h3>Description</h3>

<p>
Construct a two-stage design with a time-to-event endpoint evaluated at a pre-specified time (e.g., 6 months dosing) versus a known control rate with possible stopping for futility
after the end of Stage 1 utilizing time to event data.  The design  minimizes either the expected
duration of accrual (EDA), the expected sample size (ES), or the expected total study length
(ETSL).  The maximum combined sample size for both stages is
pre-specifed by the user.
</p>


<h3>Usage</h3>

<pre>

np.OptimDes(
            B.init, m.init, alpha, beta, param, x, n = NULL, pn = NULL,
           pt = NULL, target = c("EDA", "ETSL","ES"), recover=TRUE,
           control = OptimDesControl(), CMadj=F, ...)
</pre>


<h3>Arguments</h3>

<table summary="R argblock">
<tr valign="top"><td><code>B.init</code></td>
<td>
A vector of user-specified time points (B1, ..., Bb) that determine a
set of time intervals with uniform accrual.</td></tr>
<tr valign="top"><td><code>m.init</code></td>
<td>
The projected
number of patients that can be accrued within the time intervals determined by <code>B.init</code>.</td></tr>
<tr valign="top"><td><code>alpha</code></td>
<td>
Type I error.</td></tr>
<tr valign="top"><td><code>beta</code></td>
<td>
Type II error.</td></tr>
<tr valign="top"><td><code>param</code></td>
<td>
Events should be defined as poor outcomes (e.g. death, progression).  Computations 
and reporting are based on the proportion without an event at a 
pre-specified time, <code>x</code>.  For constructing an optimal design, 
complete event-free distributions at all times must be specified for 
the control condition (Null), and for
the alternative "effective" treatment.  Weibull distributions are currently
implemented.  <code>param</code> is a vector of length 4:  (shape null, 
scale null, shape alternative, scale alternative).  The R parameterization of the Weibull
distribution is used.</td></tr>
<tr valign="top"><td><code>x</code></td>
<td>
Pre-specified time for the event-free endpoint (e.g., 1 year).</td></tr>
<tr valign="top"><td><code>n</code></td>
<td>
User-specified combined sample size for both stages. </td></tr>
<tr valign="top"><td><code>pn</code></td>
<td>
Combined sample size for both stages specified by the
ratio of the targetted two-stage sample size to the correponding
sample size for a single-stage design.</td></tr>
<tr valign="top"><td><code>pt</code></td>
<td>
Combined sample size for both stages specified by the
ratio of the targetted two-stage study length to the correponding
study length for a single-stage design.</td></tr>
<tr valign="top"><td><code>target</code></td>
<td>
The expected duration of
accrual (EDA) is minimized with <code>target="EDA"</code>, the
expected total study length is minimized with 
<code>target="ETSL"</code>, and the expected sample size with <code>target="ES"</code>.</td></tr>
<tr valign="top"><td><code>recover</code></td>
<td>
The Simon Two-Stage design recovers alpha from the Type I errors
that would have occured if the study had not been stopped early for
futility.  This recovery allows for a slightly lower boundary for the
final test, thereby increasing power.  The default with partial data
at the interim analysis is to recover the alpha as with the standard
Simon design.  When recover=F, the optimal design is found assuming
that the boundary for the final test will not be adjusted downward
ignoring this small potential gain to ensure protection of the alpha
level even when the accrual rates and survivor functions are mis-specified. 
</td></tr>
<tr valign="top"><td><code>control</code></td>
<td>
An optional list of control settings.  See
<code><a href="OptimDesControl.html">OptimDesControl</a></code>
for the parameters that can be set and their default values.</td></tr>
<tr valign="top"><td><code>CMadj</code></td>
<td>
If CMadj=T, the ratios in <code>pn</code> and <code>pt</code> use
the exact binomial sample size in the denominator. The <code>CMadj</code>
has no effect when <code>n</code> is specified.  The default is <code>CMadj=F</code>.</td></tr>
<tr valign="top"><td><code>...</code></td>
<td>
No additional optional parameters are currently implemented</td></tr>
</table>

<h3>Details</h3>

<p>
Plots (<code><a href="plot.OptimDes.html">plot.OptimDes</a></code>) based on the ouput of
<code><a href="OptimDes.html">OptimDes</a></code> can be used to find compromise designs based on
different combined sample sizes (stages 1 and 2) with
near optimal values for both ETSL ES, and EDA.  <code>np.OptimDes</code> can be
used to compute ETSL, ES, EDA, and the other design parameters for any
specified total sample size.
</p>
<p>
The targeted combined sample size must be specified by one of
three equivalent approaches: <code>n</code>, <code>pn</code>, and <code>pt</code>.
The design calculations assume Weibull distributions for the event-free
endpoint in the treatment group, and for the (assumed known, "Null") control
distribution.  
</p>
<p>
The function <code>weibPmatch</code> can be used to select 
Weibull parameters that yield a target event-free rate at a 
specified time.
</p>


<h3>Value</h3>

<p>
A list of class <code>OptimDes</code> with the same output as function <code>OptimDes</code>.</p>

<h3>Author(s)</h3>

<p>
Bo Huang <a href="mailto:&lt;bo.huang@pfizer.com&gt;">&lt;bo.huang@pfizer.com&gt;</a> and Neal Thomas <a href="mailto:&lt;neal.thomas@pfizer.com&gt;">&lt;neal.thomas@pfizer.com&gt;</a>
</p>


<h3>References</h3>

<p>
Case M. D. and Morgan T. M. (2003) Design of Phase II cancer trials
evaluating survival probabilities. <EM>BMC Medical Research
Methodology</EM>, <B>3</B>, 7.
</p>
<p>
Lin D. Y., Shen L., Ying Z. and Breslow N. E. (1996) Group seqential
designs for monitoring survival probabilities. <EM>Biometrics</EM>,
<B>52</B>, 1033&ndash;1042.
</p>
<p>
Simon R. (1989) Optimal two-stage designs for phase II clinical
trials. <EM>Controlled Clinical Trials</EM>, <B>10</B>, 1&ndash;10.
</p>


<h3>See Also</h3>

<p>
<code><a href="OptimDes.html">OptimDes</a></code>, <code><a href="plot.OptimDes.html">plot.OptimDes</a></code>,
<code><a href="weibPmatch.html">weibPmatch</a></code>
</p>


<h3>Examples</h3>

<pre>
B.init &lt;- c(1, 2, 3, 4, 5)
m.init &lt;- c(15, 20, 25, 20, 15)
alpha &lt;- 0.05
beta &lt;- 0.1
param &lt;- c(1, 1.09, 2, 1.40)
x &lt;- 1

# H0: S0=0.40 H1: S1=0.60

np.OptimDes(B.init,m.init,alpha,beta,param,x,pt=1.1,target="ETSL")
</pre>



<hr><div align="center">[Package <em>OptimPhase2</em> version 1.9 <a href="00Index.html">Index]</a></div>

</body></html>
